Women's Financial Resources Boost Investments in Female Healthcare Advancement
In August 2025, Portfolia's Women's Health Fund IV closed, marking another successful step in the venture capital firm's mission to invest in companies that enhance women's health outcomes. This fund follows the launch of Fund II in 2020 and Fund III's closure in February 2024.
One of the key companies backed by Portfolia's Women's Health Fund IV is Gameto, which is currently advancing Fertilo—a stem cell-based fertility treatment—through Phase 3 trials and towards regulatory approval.
Mirvie, another company under Portfolia's wing, has developed a diagnostic test to predict and prevent preeclampsia, a potentially life-threatening complication during pregnancy. Meanwhile, Bone Health's Osteoboost, a pre-seed investment backed by Portfolia, was identified by the FDA as the first solution for osteopenia.
Portfolia's funds are led by veteran investors with deep women's health expertise. The firm engages its community Limited Partners (LPs) in optional monthly pitch calls, hands-on diligence, voting, teach-ins, and events.
The economics of women's health ventures are compelling, with a growing founder and expert Venture Capital (VC) base, and an expanding investor universe as women control more wealth. However, healthcare companies in the women's health sector face longer exits due to clinical trials, regulatory approvals, and reimbursement hurdles.
Interestingly, platforms often block ads for women's health products, while erectile-dysfunction campaigns face fewer hurdles. Moreover, men-specific procedures are often reimbursed more than comparable women-specific care.
Despite these challenges, Portfolia's opportunity map has widened to include conditions like dementia, autoimmune disease, cardiovascular disease, and lung disease. Lighthouse Pharmaceuticals, a company backed by Portfolia, won a $49.2 million National Institute on Aging grant.
However, federal support for early-stage clinical and disparities research is under pressure. Potential cuts to the National Institute of Health grants tied to DEI programs, the National Institute on Minority Health and Health Disparities, and the Agency for Healthcare Research and Quality could impact Portfolia's work.
Many of the investors in Portfolia's funds are healthcare professionals, reflecting the firm's commitment to supporting innovative healthcare solutions. The goal of the Portfolia Women's Health Fund IV is to convert these tailwinds into portfolio value by widening the funnel for LPs and backing companies that can meet clinical and commercial requirements.
The first FemTech Fund closed in November 2018, marking Portfolia's entry into the women's health sector. Since then, the firm has continued to invest in a diverse range of startups and businesses advancing healthcare technologies, although specific company names from these funds are not detailed in the provided search results.
